Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial
艾立布林联合吉西他滨作为复发性HER2阴性乳腺癌二线治疗的疗效和安全性:一项II期、单臂、开放标签试验
期刊:
影响因子:
doi:10.1038/s43856-026-01483-z
Xu, Xiaolu; Zhong, Jincai; Lin, Hong; Wang, Hong; Ye, Jinhui; Du, Caiwen; Wang, Zhihui; Zou, Guorong; Ouyang, Jie; Yu, Gengsheng; Wang, Yongxia; Li, Luzhen; Xu, Fei; Cui, Shien; Xiao, Mei; Peng, Peijian